1.
Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Patel P, Wang MH, Kipps TJ. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. haematol [Internet]. 2021Mar.18 [cited 2021Sep.22];106(9):2364-73. Available from: https://haematologica.org/article/view/haematol.2020.272500